Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies

Table 2

The demographics and clinical characteristics of patients in the control group.

	Age/sex	TNM	Location of metastases	Adjuvant therapy	Disease state at the beginning of the follow-up	Disease state by the end of the follow-up	PFS (month)	OS (month)
Case 1	47/M	T1N0M0			CR	CR	11	11
Case 2	70/M	T2N0M0			CR	PD	23	28
Case 3	49/M	T2N1M0	Renal hilar lymph node	IL-2 + IFN-α	PR	SD	21	29
Case 4	67/F	T1N0M0			CR	SD	31	41
Case 5	56/M	T2N0M0			CR	SD	18	32
Case 6	59/M	T2N1M1	Renal hilar lymph node&lung	IL-2 + IFN-α	PR	PD	6	15
Case 7	65/F	T2N0M0			CR	SD	23	45
Case 8	47/M	T1N0M0			CR	CR	52	52
Case 9	73/M	T2N0M0			CR	PD	11	21

CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. Age: CIK: 58.36 ± 4.673; control: 59.22 ± 3.361; ; sex: no difference between two groups (, Fisher’s exact test). TNM: no difference between two groups (, Mann–Whitney test). The median survival of the CIK group and the control group was 45 months and 29 months.